Cardiff Oncology holds special stockholder meeting
CRDF•Cardiff Oncology shareholders approved a charter amendment on October 22, 2026, increasing authorized capital stock from 170 million to 320 million shares, including an increase in authorized common stock from 150 million to 300 million shares.
1. Shareholders approve amendment
At a special meeting on October 22, 2026, Cardiff Oncology shareholders approved a charter amendment that would increase authorized capital stock from 170 million to 320 million shares. Authorized common stock would rise from 150 million to 300 million shares.
